Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039290465> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2039290465 endingPage "S243" @default.
- W2039290465 startingPage "S243" @default.
- W2039290465 abstract "We have previously demonstrated activity with immunotherapy composed of autologous tumor cells genetically modified to secrete GM-CSF (GVAX®) in advanced stage NSCLC1. In an effort to remove the requirement and variability associated with genetic transduction of individual tumors we developed a “bystander” GVAX® platform composed of autologous tumor cells mixed with an allogeneic GM- CSF secreting cell line. We conducted a phase I/II trial of this immunotherapy (3 to 12 biweekly injections) in advanced stage NSCLC. Tumors were harvested from 86 patients, tumor cell processing was successful in 76, and 49 received study treatment. The most common toxicity was local injection site reactions. Serum GM-CSF pharmacokinetics were consistent with secretion of GM- CSF from the injected cells for up to 4 days with associated transient leukocytosis confirming GM-CSF bioactivity. Evidence of treatment-induced immune activation was demonstrated; however, objective tumor responses were not seen. Compared with autologous GVAX® immunotherapy for lung cancer prepared by transduction of individual tumors with an adenoviral GM-CSF vector, GM-CSF secretion was approximately 25-fold higher with the bystander GVAX® product used in this trial. However, the frequency of injection site reactions, tumor response, time to disease progression, and survival were all less favorable in the current study in comparison to prior results. Follow-up results will be presented. 1. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte- macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96(4):326–31." @default.
- W2039290465 created "2016-06-24" @default.
- W2039290465 creator A5002341560 @default.
- W2039290465 creator A5004560643 @default.
- W2039290465 creator A5006925148 @default.
- W2039290465 creator A5015961133 @default.
- W2039290465 creator A5022802228 @default.
- W2039290465 creator A5037983975 @default.
- W2039290465 creator A5047069710 @default.
- W2039290465 creator A5055054082 @default.
- W2039290465 creator A5075665702 @default.
- W2039290465 creator A5084397317 @default.
- W2039290465 date "2006-01-01" @default.
- W2039290465 modified "2023-10-17" @default.
- W2039290465 title "631. Phase 1/2 Trial of Autologous Tumor Mixed with an Allogeneic GVAX® Immunotherapy in Advanced Stage Non-Small Cell Lung Cancer" @default.
- W2039290465 cites W2146571367 @default.
- W2039290465 doi "https://doi.org/10.1016/j.ymthe.2006.08.706" @default.
- W2039290465 hasPublicationYear "2006" @default.
- W2039290465 type Work @default.
- W2039290465 sameAs 2039290465 @default.
- W2039290465 citedByCount "0" @default.
- W2039290465 crossrefType "journal-article" @default.
- W2039290465 hasAuthorship W2039290465A5002341560 @default.
- W2039290465 hasAuthorship W2039290465A5004560643 @default.
- W2039290465 hasAuthorship W2039290465A5006925148 @default.
- W2039290465 hasAuthorship W2039290465A5015961133 @default.
- W2039290465 hasAuthorship W2039290465A5022802228 @default.
- W2039290465 hasAuthorship W2039290465A5037983975 @default.
- W2039290465 hasAuthorship W2039290465A5047069710 @default.
- W2039290465 hasAuthorship W2039290465A5055054082 @default.
- W2039290465 hasAuthorship W2039290465A5075665702 @default.
- W2039290465 hasAuthorship W2039290465A5084397317 @default.
- W2039290465 hasBestOaLocation W20392904651 @default.
- W2039290465 hasConcept C126322002 @default.
- W2039290465 hasConcept C143998085 @default.
- W2039290465 hasConcept C203014093 @default.
- W2039290465 hasConcept C2776256026 @default.
- W2039290465 hasConcept C2777478134 @default.
- W2039290465 hasConcept C2777701055 @default.
- W2039290465 hasConcept C2778170410 @default.
- W2039290465 hasConcept C2778690821 @default.
- W2039290465 hasConcept C2780674031 @default.
- W2039290465 hasConcept C502942594 @default.
- W2039290465 hasConcept C71924100 @default.
- W2039290465 hasConcept C8891405 @default.
- W2039290465 hasConceptScore W2039290465C126322002 @default.
- W2039290465 hasConceptScore W2039290465C143998085 @default.
- W2039290465 hasConceptScore W2039290465C203014093 @default.
- W2039290465 hasConceptScore W2039290465C2776256026 @default.
- W2039290465 hasConceptScore W2039290465C2777478134 @default.
- W2039290465 hasConceptScore W2039290465C2777701055 @default.
- W2039290465 hasConceptScore W2039290465C2778170410 @default.
- W2039290465 hasConceptScore W2039290465C2778690821 @default.
- W2039290465 hasConceptScore W2039290465C2780674031 @default.
- W2039290465 hasConceptScore W2039290465C502942594 @default.
- W2039290465 hasConceptScore W2039290465C71924100 @default.
- W2039290465 hasConceptScore W2039290465C8891405 @default.
- W2039290465 hasLocation W20392904651 @default.
- W2039290465 hasOpenAccess W2039290465 @default.
- W2039290465 hasPrimaryLocation W20392904651 @default.
- W2039290465 hasRelatedWork W1984674482 @default.
- W2039290465 hasRelatedWork W1991285191 @default.
- W2039290465 hasRelatedWork W1999617423 @default.
- W2039290465 hasRelatedWork W2009226744 @default.
- W2039290465 hasRelatedWork W2058205936 @default.
- W2039290465 hasRelatedWork W2074274791 @default.
- W2039290465 hasRelatedWork W2113038217 @default.
- W2039290465 hasRelatedWork W2295526809 @default.
- W2039290465 hasRelatedWork W2408444151 @default.
- W2039290465 hasRelatedWork W2584044826 @default.
- W2039290465 hasVolume "13" @default.
- W2039290465 isParatext "false" @default.
- W2039290465 isRetracted "false" @default.
- W2039290465 magId "2039290465" @default.
- W2039290465 workType "article" @default.